1. Scrip
  2. >>Business

Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts

 
• By Joseph Haas

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Metabolic disease-focused OrsoBio, Inc. made a splash on 2 November by unveiling licensing agreements with three biopharmas as well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal Watch

More from Deals